BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform

Reuters04-06 19:16

April 6 (Reuters) - Alphabet Inc GOOGL.O:

STIPPLE BIO EMERGES FROM STEALTH WITH OVERSUBSCRIBED $100 MILLION SERIES A FINANCING TO ADVANCE STP-100 INTO EARLY CLINICAL STUDIES AND ADVANCE A PRECISION ONCOLOGY PIPELINE THAT LEVERAGES ITS POINTILLIST PLATFORM
STIPPLE BIO: FINANCING CO-LED BY RA CAPITAL, A16Z BIO+HEALTH AND NEXTECH INVEST, AND EXISTING INVESTORS INCLUDING GOOGLE VENTURES
STIPPLE BIO: PROCEEDS FROM FINANCING, WHICH SHOULD FUND CO INTO 2029, TO ADVANCE LEAD CANDIDATE STP-100

Source text: ID:nGNX8yLbG7

Further company coverage: GOOGL.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625766666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-06 19:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625766666","market":"fut","top_or_hot":-1,"title":"BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform</title></head><body><p><span>April 6 (Reuters)</span><span> - </span>Alphabet Inc <span>GOOGL.O</span>:</p><ul><li><p>STIPPLE BIO EMERGES FROM STEALTH WITH OVERSUBSCRIBED $100 MILLION SERIES A FINANCING TO ADVANCE STP-100 INTO EARLY CLINICAL STUDIES AND ADVANCE A PRECISION ONCOLOGY PIPELINE THAT LEVERAGES ITS POINTILLIST PLATFORM</p></li><li><p>STIPPLE BIO: FINANCING CO-LED BY RA CAPITAL, A16Z BIO+HEALTH AND NEXTECH INVEST, AND EXISTING INVESTORS INCLUDING GOOGLE VENTURES</p></li><li><p>STIPPLE BIO: PROCEEDS FROM FINANCING, WHICH SHOULD FUND CO INTO 2029, TO ADVANCE LEAD CANDIDATE STP-100</p></li></ul><p>Source text: <span>ID:nGNX8yLbG7</span></p><p>Further company coverage: <span>GOOGL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-06 19:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform</title></head><body><p><span>April 6 (Reuters)</span><span> - </span>Alphabet Inc <span>GOOGL.O</span>:</p><ul><li><p>STIPPLE BIO EMERGES FROM STEALTH WITH OVERSUBSCRIBED $100 MILLION SERIES A FINANCING TO ADVANCE STP-100 INTO EARLY CLINICAL STUDIES AND ADVANCE A PRECISION ONCOLOGY PIPELINE THAT LEVERAGES ITS POINTILLIST PLATFORM</p></li><li><p>STIPPLE BIO: FINANCING CO-LED BY RA CAPITAL, A16Z BIO+HEALTH AND NEXTECH INVEST, AND EXISTING INVESTORS INCLUDING GOOGLE VENTURES</p></li><li><p>STIPPLE BIO: PROCEEDS FROM FINANCING, WHICH SHOULD FUND CO INTO 2029, TO ADVANCE LEAD CANDIDATE STP-100</p></li></ul><p>Source text: <span>ID:nGNX8yLbG7</span></p><p>Further company coverage: <span>GOOGL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40N03X:1","article_id":"2625766666","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625766666","pubTimestamp":1775474171,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介–Stipple Bio凭借超额认购的1亿美元A轮融资摆脱隐形状态，将STP-100推进早期临床研究，并利用其Pointillist平台推进精准肿瘤学管道","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/02baa036dd31e39331408322f40a7a6e","symbols_score_info":{"GOOW":0.6,"GOOX":0.6,"GGLS":0.6,"GGLL":0.6,"GOOY":0.6,"GOOGL":0.9,"GOU":0.6,"GOOP":0.6},"content_text":"BRIEF-Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist PlatformApril 6 (Reuters) - Alphabet Inc GOOGL.O:STIPPLE BIO EMERGES FROM STEALTH WITH OVERSUBSCRIBED $100 MILLION SERIES A FINANCING TO ADVANCE STP-100 INTO EARLY CLINICAL STUDIES AND ADVANCE A PRECISION ONCOLOGY PIPELINE THAT LEVERAGES ITS POINTILLIST PLATFORMSTIPPLE BIO: FINANCING CO-LED BY RA CAPITAL, A16Z BIO+HEALTH AND NEXTECH INVEST, AND EXISTING INVESTORS INCLUDING GOOGLE VENTURESSTIPPLE BIO: PROCEEDS FROM FINANCING, WHICH SHOULD FUND CO INTO 2029, TO ADVANCE LEAD CANDIDATE STP-100Source text: ID:nGNX8yLbG7Further company coverage: GOOGL.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625766666","isCrawlerRequest":true}